Insider Shareholders with Direct Ownership of Neoleukin Therapeutics, Inc. (NLTX)
This section provides a comprehensive overview of the insiders with direct ownership of Neoleukin Therapeutics, Inc. (NLTX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Neoleukin Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Jonathan G Drachman
President and CEO |
150,000 | 0 | 2,348,686 $0 | 3 |
Aug 24, 2021
Added 4.08%
|
|
Carl Walkey
Senior Vice President |
0 | 34,850 | 1,352,489 $0 | 26 |
Jun 16, 2021
Reduced 0.04%
|
|
Rachel Mc Minn
Chief Executive Officer |
71,400 | 0 | 1,274,259 $0 | 2 |
Mar 26, 2025
Added 1.84%
|
|
Christine Mikail Cvijic
President and CFO |
76,203 | 4,501 | 92,643 $0 | 4 |
Mar 26, 2025
Added 17.97%
|
| 55,000 | 23,687 | 37,313 $0 | 6 |
Apr 03, 2023
Reduced 9.17%
|
|
|
Stuart Cobb
Chief Scientific Officer |
27,591 | 0 | 27,591 $0 | 2 |
Mar 26, 2025
Added 20.7%
|
|
Sean Michael Smith
Interim CFO, Prin Acct Off |
22,500 | 6,294 | 21,637 $0 | 6 |
Aug 11, 2023
Reduced 5.76%
|
|
Robert Ho
Chief Financial Officer |
25,000 | 6,497 | 21,503 $0 | 2 |
Mar 17, 2021
Reduced 23.2%
|
|
Julie Jordan
Chief Medical Officer |
8,400 | 0 | 8,400 $0 | 1 |
Mar 26, 2025
Added 50.0%
|